Morgan Stanley Upgrades Abbott Based on Reacceleration
January 06, 2014 at 11:17 AM EST
In a report published Monday, Morgan Stanley analyst David Lewis upgraded Abbott Laboratories (NYSE: ABT ) from Equal-weight to Overweight based on reacceleration. Lewis noted that Abbott's 2015 revenue is expected to grow more than 100 bp faster than the company's large cap peers. The analyst added that underperformance in
